Given its demonstrated safety and efficacy, using trastuzumab to target HER-2+ tumor cells that have spread to the cerebrospinal fluid (CSF) by intrathecal administration is a plausible strategic intervention for impacting the prognosis for patients with LM metastases. This evidence concerns the gene ERBB2 and neoplasm.